Is TNYA or MREO more profitable?

Tenaya Therapeutics' return on equity of -80.56% beat Mereo BioPharma Group's return on equity. Company Net Margins Return on Equity Return on Assets Tenaya Therapeutics N/A -80.56% -65.21% Mereo BioPharma Group N/A -81.28% -70.45%

Do analysts prefer CNTN or MREO?

Mereo BioPharma Group has a consensus price target of $3.25, suggesting a potential upside of 912.46%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts clearly believe Mereo BioPharma Group is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mereo BioPharma Group 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is CNTN or MREO more profitable?

Hillstream Biopharma's return on equity of -31.50% beat Mereo BioPharma Group's return on equity. Company Net Margins Return on Equity Return on Assets Hillstream Biopharma N/A -31.50% -24.72% Mereo BioPharma Group N/A -81.28% -70.45%

Mereo BioPharma Group (MREO) Competitors

$0.32 -0.01 (-4.18%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$0.32 +0.00 (+0.62%)

As of 07:30 AM Eastern

Compare

MREO vs. TNXP, DERM, TNYA, CNTN, and MDWD

Should you buy Mereo BioPharma Group stock or one of its competitors? MarketBeat compares Mereo BioPharma Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mereo BioPharma Group include Tonix Pharmaceuticals (TNXP), Journey Medical (DERM), Tenaya Therapeutics (TNYA), Hillstream Biopharma (CNTN), and MediWound (MDWD). These companies are all part of the "pharmaceutical products" industry.

How does Mereo BioPharma Group compare to Tonix Pharmaceuticals?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

Tonix Pharmaceuticals currently has a consensus target price of $24.00, suggesting a potential upside of 105.13%. Mereo BioPharma Group has a consensus target price of $3.25, suggesting a potential upside of 912.46%. Given Mereo BioPharma Group's higher possible upside, analysts clearly believe Mereo BioPharma Group is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Mereo BioPharma Group has lower revenue, but higher earnings than Tonix Pharmaceuticals. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11M	14.23	-$124.02M	-$14.36	N/A
Mereo BioPharma Group	$500K	102.48	-$41.88M	-$0.05	N/A

Mereo BioPharma Group has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -839.52%. Tonix Pharmaceuticals' return on equity of -67.65% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

Tonix Pharmaceuticals has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 2.0% of Tonix Pharmaceuticals shares are owned by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Tonix Pharmaceuticals had 4 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 5 mentions for Tonix Pharmaceuticals and 1 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 1.87 beat Tonix Pharmaceuticals' score of 0.34 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Tonix Pharmaceuticals	Neutral
Mereo BioPharma Group	Very Positive

Summary

Tonix Pharmaceuticals beats Mereo BioPharma Group on 9 of the 17 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Journey Medical?

Mereo BioPharma Group (NASDAQ:MREO) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

In the previous week, Journey Medical had 1 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 2 mentions for Journey Medical and 1 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 1.87 beat Journey Medical's score of 1.61 indicating that Mereo BioPharma Group is being referred to more favorably in the media.

Company	Overall Sentiment
Mereo BioPharma Group	Very Positive
Journey Medical	Very Positive

Journey Medical has higher revenue and earnings than Mereo BioPharma Group. Journey Medical is trading at a lower price-to-earnings ratio than Mereo BioPharma Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	102.48	-$41.88M	-$0.05	N/A
Journey Medical	$61.86M	3.05	-$11.43M	-$0.37	N/A

Mereo BioPharma Group presently has a consensus target price of $3.25, suggesting a potential upside of 912.46%. Journey Medical has a consensus target price of $13.00, suggesting a potential upside of 89.50%. Given Mereo BioPharma Group's higher probable upside, equities research analysts plainly believe Mereo BioPharma Group is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Mereo BioPharma Group has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 6.5% of Mereo BioPharma Group shares are held by company insiders. Comparatively, 14.5% of Journey Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Mereo BioPharma Group has a net margin of 0.00% compared to Journey Medical's net margin of -14.82%. Journey Medical's return on equity of -35.57% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-81.28%	-70.45%
Journey Medical	-14.82%	-35.57%	-10.88%

Summary

Mereo BioPharma Group beats Journey Medical on 8 of the 15 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Tenaya Therapeutics?

Tenaya Therapeutics (NASDAQ:TNYA) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Tenaya Therapeutics' return on equity of -80.56% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-80.56%	-65.21%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

Mereo BioPharma Group has higher revenue and earnings than Tenaya Therapeutics. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A
Mereo BioPharma Group	$500K	102.48	-$41.88M	-$0.05	N/A

90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 2.5% of Tenaya Therapeutics shares are held by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Tenaya Therapeutics had 2 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 3 mentions for Tenaya Therapeutics and 1 mentions for Mereo BioPharma Group. Tenaya Therapeutics' average media sentiment score of 1.87 equaled Mereo BioPharma Group'saverage media sentiment score.

Company	Overall Sentiment
Tenaya Therapeutics	Very Positive
Mereo BioPharma Group	Very Positive

Tenaya Therapeutics has a beta of 2.83, suggesting that its share price is 183% more volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

Tenaya Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 378.18%. Mereo BioPharma Group has a consensus target price of $3.25, suggesting a potential upside of 912.46%. Given Mereo BioPharma Group's higher probable upside, analysts clearly believe Mereo BioPharma Group is more favorable than Tenaya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Tenaya Therapeutics beats Mereo BioPharma Group on 9 of the 14 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Hillstream Biopharma?

Hillstream Biopharma (NASDAQ:CNTN) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Hillstream Biopharma has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

1.2% of Hillstream Biopharma shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 3.3% of Hillstream Biopharma shares are held by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Hillstream Biopharma had 1 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 2 mentions for Hillstream Biopharma and 1 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 1.87 beat Hillstream Biopharma's score of 0.93 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Hillstream Biopharma	Positive
Mereo BioPharma Group	Very Positive

Mereo BioPharma Group has a consensus price target of $3.25, suggesting a potential upside of 912.46%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts clearly believe Mereo BioPharma Group is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Hillstream Biopharma's return on equity of -31.50% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

Hillstream Biopharma has higher earnings, but lower revenue than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A
Mereo BioPharma Group	$500K	102.48	-$41.88M	-$0.05	N/A

Summary

Mereo BioPharma Group beats Hillstream Biopharma on 8 of the 14 factors compared between the two stocks.

How does Mereo BioPharma Group compare to MediWound?

MediWound (NASDAQ:MDWD) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

MediWound currently has a consensus price target of $34.00, indicating a potential upside of 138.60%. Mereo BioPharma Group has a consensus price target of $3.25, indicating a potential upside of 912.46%. Given Mereo BioPharma Group's higher probable upside, analysts clearly believe Mereo BioPharma Group is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, MediWound and MediWound both had 1 articles in the media. MediWound's average media sentiment score of 1.87 equaled Mereo BioPharma Group'saverage media sentiment score.

Company	Overall Sentiment
MediWound	Very Positive
Mereo BioPharma Group	Very Positive

Mereo BioPharma Group has a net margin of 0.00% compared to MediWound's net margin of -180.30%. MediWound's return on equity of -67.22% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-180.30%	-67.22%	-31.87%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

46.8% of MediWound shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 9.2% of MediWound shares are owned by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

MediWound has higher revenue and earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	10.80	-$23.88M	-$2.26	N/A
Mereo BioPharma Group	$500K	102.48	-$41.88M	-$0.05	N/A

MediWound has a beta of 0.14, suggesting that its stock price is 86% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

Summary

Mereo BioPharma Group beats MediWound on 7 of the 13 factors compared between the two stocks.

Get Mereo BioPharma Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MREO vs. The Competition

Export

Metric	Mereo BioPharma Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$53.47M	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-6.42	20.85	27.12	24.26
Price / Sales	102.48	314.01	587.25	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	1.23	8.49	10.89	6.29
Net Income	-$41.88M	$23.83M	$3.58B	$330.66M
7 Day Performance	-4.04%	-3.56%	-2.11%	-1.35%
1 Month Performance	5.25%	6.31%	3.28%	-0.64%
1 Year Performance	-81.34%	48.30%	26.33%	19.08%

Mereo BioPharma Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MREO Mereo BioPharma Group	3.2211 of 5 stars	$0.32 -4.2%	$3.25 +912.5%	-80.1%	$53.47M	$500K	N/A	40	Positive News
TNXP Tonix Pharmaceuticals	3.8814 of 5 stars	$12.45 -2.0%	$24.00 +92.8%	-71.4%	$198.45M	$13.11M	N/A	50	News Coverage
DERM Journey Medical	3.4787 of 5 stars	$7.09 -1.8%	$13.00 +83.4%	-4.1%	$195.19M	$61.86M	N/A	90
TNYA Tenaya Therapeutics	2.9865 of 5 stars	$0.90 +3.5%	$4.00 +346.4%	+22.4%	$194.43M	N/A	N/A	110	News Coverage Positive News Gap Down
CNTN Hillstream Biopharma	0.5089 of 5 stars	$2.51 -2.5%	N/A	N/A	$193.19M	N/A	N/A	2	News Coverage Analyst Downgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MREO) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mereo BioPharma Group (MREO) Competitors

MREO vs. TNXP, DERM, TNYA, CNTN, and MDWD

How does Mereo BioPharma Group compare to Tonix Pharmaceuticals?

Summary

How does Mereo BioPharma Group compare to Journey Medical?

Summary

How does Mereo BioPharma Group compare to Tenaya Therapeutics?

Summary

How does Mereo BioPharma Group compare to Hillstream Biopharma?

Summary

How does Mereo BioPharma Group compare to MediWound?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO vs. The Competition

Mereo BioPharma Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mereo BioPharma Group (MREO) Competitors

MREO vs. TNXP, DERM, TNYA, CNTN, and MDWD

How does Mereo BioPharma Group compare to Tonix Pharmaceuticals?

Do analysts recommend TNXP or MREO?

Which has better earnings & valuation, TNXP or MREO?

Is TNXP or MREO more profitable?

Which has more volatility and risk, TNXP or MREO?

Do institutionals & insiders have more ownership in TNXP or MREO?

Does the media refer more to TNXP or MREO?

Summary

How does Mereo BioPharma Group compare to Journey Medical?

Does the media prefer MREO or DERM?

Which has stronger valuation & earnings, MREO or DERM?

Do analysts rate MREO or DERM?

Which has more volatility and risk, MREO or DERM?

Do insiders and institutionals hold more shares of MREO or DERM?

Is MREO or DERM more profitable?

Summary

How does Mereo BioPharma Group compare to Tenaya Therapeutics?

Is TNYA or MREO more profitable?

Which has preferable valuation & earnings, TNYA or MREO?

Do insiders & institutionals have more ownership in TNYA or MREO?

Does the media refer more to TNYA or MREO?

Which has more volatility & risk, TNYA or MREO?

Do analysts recommend TNYA or MREO?

Summary

How does Mereo BioPharma Group compare to Hillstream Biopharma?

Which has more volatility & risk, CNTN or MREO?

Do insiders and institutionals have more ownership in CNTN or MREO?

Does the media favor CNTN or MREO?

Do analysts prefer CNTN or MREO?

Is CNTN or MREO more profitable?

Which has stronger earnings & valuation, CNTN or MREO?

Summary

How does Mereo BioPharma Group compare to MediWound?

Do analysts rate MDWD or MREO?

Does the media refer more to MDWD or MREO?

Is MDWD or MREO more profitable?

Do institutionals and insiders believe in MDWD or MREO?

Which has preferable valuation & earnings, MDWD or MREO?

Which has more volatility and risk, MDWD or MREO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO vs. The Competition

Mereo BioPharma Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools